GlassScriptPhysician profile
Kevin M Dineen
NPI 1639175516
$13,048.88
in general payments reported to CMS, 2019-2025
48 companies · $1,959 in 2025
The $1,959 reported for 2025 was more than what 75% of Pulmonary Disease providers received nationally (typical 2025 total: $500).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,873 · 2020: $1,521 · 2021: $1,284 · 2022: $1,671 · 2023: $2,818 · 2024: $1,924 · 2025: $1,959.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,859 · Travel and Lodging: $751 · Education: $89.59.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,859.41 |
| Travel and Lodging | $751.33 |
| Education | $89.59 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $1,700.05 | 2019-2025 | Trelegy Ellipta, Nucala, Arexvy |
| Astrazeneca Pharmaceuticals LP | $1,670.34 | 2019-2025 | Airsupra, Fasenra, Breztri |
| Boehringer Ingelheim Pharmaceuticals, INC. | $1,270.52 | 2019-2025 | Ofev, Jascayd, Stiolto Respimat |
| Intuitive Surgical, INC. | $955.72 | 2023-2025 | Da Vinci Surgical System |
| Insmed, INC. | $931.04 | 2019-2025 | Arikayce, Brinsupri |
| Genzyme Corporation | $800.18 | 2019-2025 | |
| Actelion Pharmaceuticals US, INC. | $797.06 | 2019-2025 | Uptravi, Opsumit |
| United Therapeutics Corporation | $654.13 | 2021-2025 | Tyvaso, Tyvaso |
| Regeneron Healthcare Solutions, INC. | $620.02 | 2019-2025 | Dupixent |
| Philips North America LLC | $475.16 | 2019-2023 | |
| Mallinckrodt Hospital Products INC. | $355.30 | 2021-2024 | Acthar |
| Mylan Specialty L.P. | $327.44 | 2019-2024 | Yupelri |
| Grifols USA, LLC | $312.72 | 2022-2025 | Prolastin-C Liquid, Xembify |
| Merck Sharp & Dohme LLC | $307.30 | 2019-2025 | Winrevair, Zerbaxa, Keytruda |
| Verona Pharma, INC. | $266.07 | 2025 | Ohtuvayre |
Show all 48 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kevin Dineen listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.